Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
81,149,970
-
Total 13F shares
-
28,010,905
-
Share change
-
+24,367,722
-
Total reported value
-
$600,997,818
-
Put/Call ratio
-
6.7%
-
Price per share
-
$21.52
-
Number of holders
-
54
-
Value change
-
+$524,495,527
-
Number of buys
-
42
-
Number of sells
-
7
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) as of Q4 2023
As of 31 Dec 2023,
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,010,905 shares.
The largest 10 holders included
FMR LLC, PERCEPTIVE ADVISORS LLC, VR Adviser, LLC, RTW INVESTMENTS, LP, Deep Track Capital, LP, COMMODORE CAPITAL LP, Avoro Capital Advisors LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Cormorant Asset Management, LP, and EcoR1 Capital, LLC.
This page lists
54
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.